Cargando…
Induction versus adjuvant chemotherapy combined with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study
Background: Currently available evidence favors the combination of chemotherapy with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma (LANPC). However, the optimal timing for additional chemotherapy is unclear. This study was conducted to compare the efficacy and toxi...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9467407/ https://www.ncbi.nlm.nih.gov/pubmed/36036759 http://dx.doi.org/10.18632/aging.204246 |
_version_ | 1784788188110258176 |
---|---|
author | Mu, Xiaoli Liu, Hongyan Wu, Juan Chen, Shi Peng, Xingchen Wang, Jingjing Wei, Zhigong He, Ling Liu, Jiyan Lu, Zejun Su, Yonglin |
author_facet | Mu, Xiaoli Liu, Hongyan Wu, Juan Chen, Shi Peng, Xingchen Wang, Jingjing Wei, Zhigong He, Ling Liu, Jiyan Lu, Zejun Su, Yonglin |
author_sort | Mu, Xiaoli |
collection | PubMed |
description | Background: Currently available evidence favors the combination of chemotherapy with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma (LANPC). However, the optimal timing for additional chemotherapy is unclear. This study was conducted to compare the efficacy and toxicity of induction chemotherapy plus concurrent chemoradiotherapy (IC+CCRT) versus concurrent chemoradiotherapy plus adjuvant chemotherapy (CCRT+AC). Methods: Two medical centers in China enrolled patients with LANPC (stage III-IVB) between January 2009 and May 2020. Through the use of propensity score matching (PSM), baseline characteristics were balanced. The primary endpoint was overall survival (OS), which was evaluated by the Kaplan-Meier method and log-rank test. Potential independent prognostic factors were identified using univariate and multivariate Cox proportional hazard analyses. Based on the chi-squared test, we compared the adverse events associated with treatment between the groups. Results: After the implementation of PSM, 159 patients treated with IC+CCRT and 72 patients treated with CCRT+AC were eventually enrolled in this study. There was no significant difference between patients treated with IC+CCRT and CCRT+AC in terms of 3-year OS (94.7% versus 90.9%, p=0.816), progression-free survival (PFS) (91.2% versus 83.1%, p=0.588), locoregional recurrence-free survival (LRFS) (92.5% versus 81.8%, p=0.478), or distant metastasis-free survival (DMFS) (93.4% versus 88.2%, p=0.783). There was no prognostic significance of the treatment for OS, PFS, LRFS, or DMFS (all p > 0.05) in the univariate and multivariate analyses. Patients treated with CCRT+AC had a higher incidence of grade 3 to 4 leucopenia (p=0.001) and neutropenia (p=0.001) than those treated with IC+CCRT. Conclusions: IC plus CCRT achieved comparable survival outcomes to CCRT plus AC and had a lower incidence of toxicity. |
format | Online Article Text |
id | pubmed-9467407 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Impact Journals |
record_format | MEDLINE/PubMed |
spelling | pubmed-94674072022-09-14 Induction versus adjuvant chemotherapy combined with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study Mu, Xiaoli Liu, Hongyan Wu, Juan Chen, Shi Peng, Xingchen Wang, Jingjing Wei, Zhigong He, Ling Liu, Jiyan Lu, Zejun Su, Yonglin Aging (Albany NY) Research Paper Background: Currently available evidence favors the combination of chemotherapy with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma (LANPC). However, the optimal timing for additional chemotherapy is unclear. This study was conducted to compare the efficacy and toxicity of induction chemotherapy plus concurrent chemoradiotherapy (IC+CCRT) versus concurrent chemoradiotherapy plus adjuvant chemotherapy (CCRT+AC). Methods: Two medical centers in China enrolled patients with LANPC (stage III-IVB) between January 2009 and May 2020. Through the use of propensity score matching (PSM), baseline characteristics were balanced. The primary endpoint was overall survival (OS), which was evaluated by the Kaplan-Meier method and log-rank test. Potential independent prognostic factors were identified using univariate and multivariate Cox proportional hazard analyses. Based on the chi-squared test, we compared the adverse events associated with treatment between the groups. Results: After the implementation of PSM, 159 patients treated with IC+CCRT and 72 patients treated with CCRT+AC were eventually enrolled in this study. There was no significant difference between patients treated with IC+CCRT and CCRT+AC in terms of 3-year OS (94.7% versus 90.9%, p=0.816), progression-free survival (PFS) (91.2% versus 83.1%, p=0.588), locoregional recurrence-free survival (LRFS) (92.5% versus 81.8%, p=0.478), or distant metastasis-free survival (DMFS) (93.4% versus 88.2%, p=0.783). There was no prognostic significance of the treatment for OS, PFS, LRFS, or DMFS (all p > 0.05) in the univariate and multivariate analyses. Patients treated with CCRT+AC had a higher incidence of grade 3 to 4 leucopenia (p=0.001) and neutropenia (p=0.001) than those treated with IC+CCRT. Conclusions: IC plus CCRT achieved comparable survival outcomes to CCRT plus AC and had a lower incidence of toxicity. Impact Journals 2022-08-26 /pmc/articles/PMC9467407/ /pubmed/36036759 http://dx.doi.org/10.18632/aging.204246 Text en Copyright: © 2022 Mu et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Mu, Xiaoli Liu, Hongyan Wu, Juan Chen, Shi Peng, Xingchen Wang, Jingjing Wei, Zhigong He, Ling Liu, Jiyan Lu, Zejun Su, Yonglin Induction versus adjuvant chemotherapy combined with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study |
title | Induction versus adjuvant chemotherapy combined with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study |
title_full | Induction versus adjuvant chemotherapy combined with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study |
title_fullStr | Induction versus adjuvant chemotherapy combined with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study |
title_full_unstemmed | Induction versus adjuvant chemotherapy combined with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study |
title_short | Induction versus adjuvant chemotherapy combined with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study |
title_sort | induction versus adjuvant chemotherapy combined with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9467407/ https://www.ncbi.nlm.nih.gov/pubmed/36036759 http://dx.doi.org/10.18632/aging.204246 |
work_keys_str_mv | AT muxiaoli inductionversusadjuvantchemotherapycombinedwithconcurrentchemoradiotherapyinlocoregionallyadvancednasopharyngealcarcinomaaretrospectivecohortstudy AT liuhongyan inductionversusadjuvantchemotherapycombinedwithconcurrentchemoradiotherapyinlocoregionallyadvancednasopharyngealcarcinomaaretrospectivecohortstudy AT wujuan inductionversusadjuvantchemotherapycombinedwithconcurrentchemoradiotherapyinlocoregionallyadvancednasopharyngealcarcinomaaretrospectivecohortstudy AT chenshi inductionversusadjuvantchemotherapycombinedwithconcurrentchemoradiotherapyinlocoregionallyadvancednasopharyngealcarcinomaaretrospectivecohortstudy AT pengxingchen inductionversusadjuvantchemotherapycombinedwithconcurrentchemoradiotherapyinlocoregionallyadvancednasopharyngealcarcinomaaretrospectivecohortstudy AT wangjingjing inductionversusadjuvantchemotherapycombinedwithconcurrentchemoradiotherapyinlocoregionallyadvancednasopharyngealcarcinomaaretrospectivecohortstudy AT weizhigong inductionversusadjuvantchemotherapycombinedwithconcurrentchemoradiotherapyinlocoregionallyadvancednasopharyngealcarcinomaaretrospectivecohortstudy AT heling inductionversusadjuvantchemotherapycombinedwithconcurrentchemoradiotherapyinlocoregionallyadvancednasopharyngealcarcinomaaretrospectivecohortstudy AT liujiyan inductionversusadjuvantchemotherapycombinedwithconcurrentchemoradiotherapyinlocoregionallyadvancednasopharyngealcarcinomaaretrospectivecohortstudy AT luzejun inductionversusadjuvantchemotherapycombinedwithconcurrentchemoradiotherapyinlocoregionallyadvancednasopharyngealcarcinomaaretrospectivecohortstudy AT suyonglin inductionversusadjuvantchemotherapycombinedwithconcurrentchemoradiotherapyinlocoregionallyadvancednasopharyngealcarcinomaaretrospectivecohortstudy |